These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 9339201)
1. [P53 mutations, asset or disadvantage for cancer chemotherapy]. Jacquemin-Sablon A Bull Cancer; 1997 Jul; 84(7):741-6. PubMed ID: 9339201 [TBL] [Abstract][Full Text] [Related]
2. p53 and response to chemotherapy and radiotherapy. Ruley HE Important Adv Oncol; 1996; ():37-56. PubMed ID: 8791127 [No Abstract] [Full Text] [Related]
3. [Tumor suppressor gene p53: mechanisms of action in cell proliferation and death]. Mendoza-Rodríguez CA; Cerbón MA Rev Invest Clin; 2001; 53(3):266-73. PubMed ID: 11496714 [TBL] [Abstract][Full Text] [Related]
4. [Tumor suppressor p53 gene: a potential target for cancer therapy?]. Soussi T Bull Cancer; 1997 Jul; 84(7):753-6. PubMed ID: 9339203 [No Abstract] [Full Text] [Related]
5. Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor. King TC; Estalilla OC; Safran H Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):4-11. PubMed ID: 10210535 [TBL] [Abstract][Full Text] [Related]
6. [Cell cycle regulation after exposure to ionizing radiation]. Teyssier F; Bay JO; Dionet C; Verrelle P Bull Cancer; 1999 Apr; 86(4):345-57. PubMed ID: 10341340 [TBL] [Abstract][Full Text] [Related]
7. Induction of apoptosis and cell cycle-specific change in expression of p53 in normal lymphocytes and MOLT-4 leukemic cells by nitrogen mustard. Bhatia U; Danishefsky K; Traganos F; Darzynkiewicz Z Clin Cancer Res; 1995 Aug; 1(8):873-80. PubMed ID: 9816057 [TBL] [Abstract][Full Text] [Related]
8. The dual role of mutant p53 protein in chemosensitivity of human cancers. Mueller H; Eppenberger U Anticancer Res; 1996; 16(6B):3845-8. PubMed ID: 9042268 [TBL] [Abstract][Full Text] [Related]
9. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line. Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698 [TBL] [Abstract][Full Text] [Related]
10. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332 [TBL] [Abstract][Full Text] [Related]
11. p53 apoptotic response to DNA damage dependent on bcl2 but not bax in head and neck squamous cell carcinoma lines. Crowe DL; Sinha UK Head Neck; 2006 Jan; 28(1):15-23. PubMed ID: 16302195 [TBL] [Abstract][Full Text] [Related]
12. Bcl2-negative MCF7 cells overexpress p53: implications for the cell cycle and sensitivity to cytotoxic drugs. Poliseno L; Mariani L; Collecchi P; Piras A; Zaccaro L; Rainaldi G Cancer Chemother Pharmacol; 2002 Aug; 50(2):127-30. PubMed ID: 12172977 [TBL] [Abstract][Full Text] [Related]
13. [Antioncogene p53 and apoptosis response: new hypotheses on the molecular bases of tumor resistance to radiotherapy]. Corvò R Radiol Med; 1996 Sep; 92(3):298-302. PubMed ID: 8975319 [TBL] [Abstract][Full Text] [Related]
14. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686 [TBL] [Abstract][Full Text] [Related]
15. Retinoic acid-mediated G1-S-phase arrest of normal human mammary epithelial cells is independent of the level of p53 protein expression. Seewaldt VL; Dietze EC; Johnson BS; Collins SJ; Parker MB Cell Growth Differ; 1999 Jan; 10(1):49-59. PubMed ID: 9950218 [TBL] [Abstract][Full Text] [Related]
16. Relaxed cell-cycle arrests and propagation of unrepaired chromosomal damage in cancer cell lines with wild-type p53. Olivier M; Bautista S; Vallès H; Theillet C Mol Carcinog; 1998 Sep; 23(1):1-12. PubMed ID: 9766432 [TBL] [Abstract][Full Text] [Related]
17. Endogenous p53 regulation and function in early stage Friend virus-induced tumor progression differs from that following DNA damage. Kelley LL; Hicks GG; Hsieh FF; Prasher JM; Green WF; Miller MD; Eide EJ; Ruley HE Oncogene; 1998 Sep; 17(9):1119-30. PubMed ID: 9764822 [TBL] [Abstract][Full Text] [Related]
18. p53 mutation heterogeneity in cancer. Soussi T; Lozano G Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939 [TBL] [Abstract][Full Text] [Related]
19. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679 [TBL] [Abstract][Full Text] [Related]
20. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Georges SA; Biery MC; Kim SY; Schelter JM; Guo J; Chang AN; Jackson AL; Carleton MO; Linsley PS; Cleary MA; Chau BN Cancer Res; 2008 Dec; 68(24):10105-12. PubMed ID: 19074876 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]